Table 1. Summary of 21 studies investigating association between MMP polymorphisms and COPD risk.
| sample size | lung function of COPD | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| author | year | ethnicity | case | control | age matched | smoking index matched | FEV1/FVC% | FEV1/pre% | COPD diagnosis | genotype identification |
| Cai | 2010 | Asian | 80 | 90 | Yes | Yes | not mentioned | not mentioned | CMA guideline # | PCR-RFLP |
| Cheng | 2009 | Asian | 184 | 212 | Yes | Yes | 45.8 ± 8.6 | 47.2 ± 16.3 | ATS | PCR-RFLP |
| Diemen # | 2011 | Caucasian | 178 | 1117 | Yes | Yes | not mentioned | not mentioned | GOLD | Taqman |
| Enewold | 2012 | African | 44 | 147 | Yes | No | not mentioned | not mentioned | not mentioned | MassARRAY iPLEXTM platform |
| Caucasian | 123 | 191 | Yes | No | ||||||
| Han | 2006 | Asian | 60 | 52 | Yes | Yes | not mentioned | 45.2 ± 12.6 | CMA guideline # | PCR-RFLP |
| Haq | 2010 | Caucasian | 977 | 876 | No | No | 47.4 ± 12.1 | 43.0 ± 15.1 | GOLD | KASPar assay |
| Hersh | 2005 | Caucasian | 304 | 441 | Yes | No | 41.5 ± 8.2 | 24.8 ± 6.5 | NETT inclusion standard ## | Taqman |
| Hua | 2010 | Asian | 180 | 180 | Yes | Yes | not mentioned | 50.3 ± 3.6 | CMA guideline # | PCR-RFLP |
| Ito | 2005 | Asian | 84 | 85 | No | No | 45.3 ± 9.8 | 44.9 ± 17.4 | GOLD | PCR-RFLP |
| Korytina | 2008 | Caucasian | 318 | 319 | No | Yes | not mentioned | 39.4 ± 17.8 | GOLD | PCR-RFLP |
| Korytina | 2012 | Caucasian | 391 | 514 | No | No | 58.7 ± 13.7 | 41.7 ± 19.3 | GOLD | PCR-RFLP |
| Lee | 2010 | Asian | 301 | 333 | No | No | 49.4 ± 13.1 | 63.0 ± 26.2 | GOLD | ABI sequencer |
| Minematsu | 2001 | Asian | 45 | 65 | Yes | Yes | 49 ± 17 | not mentioned | LAA score on chest CT-scans, LAA > 8.0 | PCR-RFLP |
| Santus | 2009 | Caucasian | 147 | 133 | Yes | No | not mentioned | 50.3 ± 16 | GOLD | ABI sequencer |
| Schirmer | 2009 | Caucasian | 111 | 101 | No | Unknown | not mentioned | not mentioned | GOLD | PCR-RFLP |
| Sun | 2005 | Asian | 59 | 109 | Yes | Yes | not mentioned | not mentioned | CMA guideline # | PCR-RFLP |
| Sun | 2012 | Asian | 80 | 74 | Yes | Yes | 47.28 ± 10.09 | 41.29 ± 15.59 | CMA guideline # | PCR-RFLP |
| Tesfaigzi | 2006 | Caucasian* | 123 | 262 | No | No | not mentioned | 58.6 (19–99)** | GOLD | PCR-RFLP |
| Zhang | 2004 | Asian | 148 | 197 | Yes | Yes | 52.44 ± 10.77 | 52.3 ± 18.24 | CMA guideline # | PCR-RFLP |
| Zhang | 2005 | Asian | 147 | 120 | No | Yes | 53 ± 11 | 53 ± 18 | CMA guideline # | PCR-RFLP |
| Zhou | 2004 | Asian | 100 | 98 | Yes | Yes | 54.56 ± 9.85 | 63.14 ± 17.37 | GOLD | PCR-RFLP |
*The people recruited in this study consist of non-Hispanic white, Hispanic and others.
**the data were shown as average (min - max).
#The guideline was published by Chinese Medical Association (CMA) for diagnosis and treatment of COPD in 2002.
##The cases were from NETT (National Emphysema Treatment Trial) according to standard as follows: 1. FEV1 < 45% prediction, evidence of hyperinflation on pulmonary function testing; 2. Bilateral emphysema confirmed by HRCT.